Emilia Javorsky
speaker
1,653 appearances
2 recordings
1 series
first heard Mar 2026
last heard 20 Mar
Emilia Javorsky’s voice in public audio — every appearance, attributed to the second.
Trend
recordings per month · last 12 monthsRecordings per month over the last 12 months — 2 in all, peaking in Mar 2026 with 2.
Appearances
or greatly increased annual new drug approvals.
An abundance of knowledge and an oversupply of brilliant scientists have not moved the needle on more cures.
The superintelligence narrative shapes capital allocation, policy priorities, and public expectations.
The National Cancer Institute's 2025 budget, which funds most fundamental cancer research in the United States, was $7.2 billion.
a mere 1.3% of the $540 billion projected total spend by private markets to build out superintelligence in 2026.
The opportunity cost for medical progress is significant.
The share of biotech funding is at a 20-year low.
while unprecedented sums of VC dollars are directed to the development of superintelligence.
The markets, at least, believe the hype.
The obsession with the pursuit of multibillion-dollar superintelligence obscures what AI can already do nearly for free.
Today's AI capabilities already deliver real medical value, not through big tech's pursuit of godlike machines, but through targeted solutions for specific problems.
Even Google's DeepMind's AlphaFold succeeded by focusing on one well-defined challenge, protein folding.
Across pharma companies, biotech startups, and academic labs, AI is already cracking concrete bottlenecks in cancer treatment, drug discovery, toxicity prediction, and clinical trial efficiency.
This is where investment belongs.
But developing practical AI tools to solve problems and remove friction is fundamentally different from chasing super intelligence genies that assume raw computing power will magically cure all ills.
Every complex problem demands we ask, is this bottlenecked by insufficient intelligence?
If not, what's actually blocking progress?
If so, can current AI solve it?
Today's AI already addresses real intelligence and efficiency gaps in drug development.
The deeper question remains.
Showing 681–700 of 1,653 · page 35 of 83
← Previous
Next →